Surmodics (NASDAQ: SRDX) and H. B. Fuller Company (NYSE:FUL) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitabiliy, risk, earnings, valuation and institutional ownership.

Risk & Volatility

Surmodics has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, H. B. Fuller Company has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500.

Earnings and Valuation

This table compares Surmodics and H. B. Fuller Company’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Surmodics $73.39 million 4.54 $21.68 million $0.71 35.35
H. B. Fuller Company $2.12 billion 1.25 $273.29 million $2.34 22.34

H. B. Fuller Company has higher revenue and earnings than Surmodics. H. B. Fuller Company is trading at a lower price-to-earnings ratio than Surmodics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

86.5% of Surmodics shares are owned by institutional investors. Comparatively, 93.7% of H. B. Fuller Company shares are owned by institutional investors. 6.4% of Surmodics shares are owned by insiders. Comparatively, 3.1% of H. B. Fuller Company shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Dividends

H. B. Fuller Company pays an annual dividend of $0.60 per share and has a dividend yield of 1.1%. Surmodics does not pay a dividend. H. B. Fuller Company pays out 25.6% of its earnings in the form of a dividend. H. B. Fuller Company has raised its dividend for 47 consecutive years.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Surmodics and H. B. Fuller Company, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Surmodics 0 2 0 0 2.00
H. B. Fuller Company 0 3 1 0 2.25

Surmodics presently has a consensus price target of $33.00, indicating a potential upside of 31.47%. H. B. Fuller Company has a consensus price target of $51.50, indicating a potential downside of 1.49%. Given Surmodics’ higher probable upside, research analysts plainly believe Surmodics is more favorable than H. B. Fuller Company.

Profitability

This table compares Surmodics and H. B. Fuller Company’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Surmodics 12.88% 10.95% 8.98%
H. B. Fuller Company 5.65% 13.81% 6.21%

Summary

H. B. Fuller Company beats Surmodics on 10 of the 17 factors compared between the two stocks.

About Surmodics

Surmodics, Inc. is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company’s Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device. The Company’s In Vitro Diagnostics segment manufactures or sells components for in vitro diagnostic immunoassay and molecular tests. The In Vitro Diagnostics segment manufactures and sells surface coatings to the diagnostic, biomedical research and life science markets. In Vitro Diagnostics segment offers protein stabilization reagents, substrates, antigens and surface coatings.

About H. B. Fuller Company

H.B. Fuller Company is a formulator, manufacturer and marketer of adhesives, sealants and other specialty chemical products. The Company’s segments include Americas Adhesives, Europe, India, Middle East and Africa (EIMEA), Asia Pacific, Construction Products and Engineering Adhesives. The Americas Adhesives, EIMEA and Asia Pacific operating segments produce and supply industrial adhesives products for applications in various markets, including durable assembly, nonwoven and hygiene, and textile. The Construction Products operating segment includes products used for tile setting and heating, ventilation and air conditioning and insulation applications. The Engineering Adhesives operating segment produces and supplies industrial adhesives to the transportation, appliance and heavy machinery markets, among others. As of December 3, 2016, its sales operations spanned 38 countries in North America, Europe, Latin America, the Asia Pacific region, India, the Middle East and Africa.

Receive News & Ratings for Surmodics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.